Combination of STING agonist with anti-vascular RGD-(KLAKLAK)2 peptide as a novel anti-tumor therapy

Justyna Czapla,Alina Drzyzga,Joanna Ciepła,Sybilla Matuszczak,Magdalena Jarosz-Biej,Ewelina Pilny,Tomasz Cichoń,Ryszard Smolarczyk

DOI: https://doi.org/10.1007/s00262-024-03732-3

IF: 6.63

2024-06-05

Cancer Immunology Immunotherapy

Abstract:Immunotherapy is one of the most promising anti-cancer treatment. It involves activating the host's own immune system to eliminate cancer cells. Activation of cGAS-STING pathway is promising therapeutic approach for cancer immunotherapy. However, in human clinical trials, targeting cGAS-STING pathway results in insufficient or unsustainable anti-tumor response. To enhance its effectiveness, combination with other anti-cancer therapies seems essential to achieve synergistic systemic anti-tumor response.

oncology,immunology

What problem does this paper attempt to address?

The aim of this paper is to address the issue of whether combining the STING agonist (cGAMP) with the anti-vascular peptide RGD-(KLAKLAK)2 can produce better anti-tumor effects in low-immunogenic tumors. Specifically, the study focuses on the response of tumors with different STING protein and αvβ3 integrin statuses to this combination therapy.

The paper points out that although activation of the cGAS-STING pathway has shown potential in cancer immunotherapy, the use of STING agonists alone in clinical trials often leads to insufficient or unsustainable anti-tumor responses. Therefore, the researchers hope to enhance its efficacy by combining it with other anti-cancer therapies. This paper mainly explores the effect of combining the STING agonist with the vascular-targeting peptide RGD-(KLAKLAK)2 and experimentally verifies the mechanism and effectiveness of this combination therapy in different types of tumor models.